STALLERGENES-GREER
26.4.2023 10:27:33 CEST | Business Wire | Press release
Stallergenes Greer, a biopharmaceutical company specialising in the research, diagnosis and treatment of respiratory allergies, is pleased to announce its strategic direction for the Stallergenes Greer Foundation.
The Stallergenes Greer Foundation, under the aegis of the Fondation de France, aims to build healthier futures for all by focusing on three key areas:
- Advancing scientific research to boost innovation and precision medicine;
- Supporting academic initiatives to further develop future generations of allergy healthcare professionals;
- Engaging in climate action and environmental protection to advance the prevention and treatment of allergies.
The comprehensive approach adopted by the Stallergenes Greer Foundation aims to serve the One Health Initiative that has been formally endorsed by the World Health Organisation (WHO) in particular, and which calls for “the collaborative efforts of multiple disciplines working locally, nationally, and globally to attain optimal health for people, animals and our environment.”
“The strategic direction of the Stallergenes Greer Foundation reflects our unwavering engagement to advance precision medicine and science in the field of allergy for the benefit of society and will contribute to breakthrough collaborations to address complex challenges in allergy and environmental health. I would like to take this opportunity to thank the members of our Scientific Board whose experience and vision are strong assets for the foundation,” stated Michele Antonelli, CEO of Stallergenes Greer and Chairman of the Stallergenes Greer Foundation.
The Stallergenes Greer Foundation will support innovative research projects, encompassing fundamental, applied, environmental and societal research, as well as education.
In 2023, the foundation will allocate up to €150,000 for outstanding work led either by a young scientist or a mid-career scientist to advance precision medicine in the field of allergy, or outstanding work in the environmental field to advance the prevention and treatment of allergies.
The Stallergenes Greer Foundation is governed by a Board of Trustees, which itself brings together a Managing Board and a Scientific Board:
The Managing Board is comprised of Stallergenes Greer senior executives:
- Michele Antonelli, CEO,
- Amer Jaber, EVP Operations Europe,
- Dominique Pezziardi, General Manager France, Belgium and Luxembourg - Global Head of Pricing and Market Access,
- Catherine Kress, Head of Communications and Corporate responsibility.
The Scientific Board is comprised of renowned scientific and medical experts:
- Pascal Demoly, Professor of Pulmonology and Head of Department at the University Hospital, Montpellier (France),
- Alessandro Fiocchi, MD, Director of Allergy at Bambino Gesù Children’s Hospital, Rome, Vatican City (Italy),
- Carla Irani, Associate Professor of Internal Medicine and Clinical Immunology, Allergology - Immunological Asthma at Hôtel Dieu de France University Medical Center, Beirut (Lebanon),
- Kari Nadeau, MD, PhD, Chair of the Department of Environmental Health at the Harvard T.H. Chan School of Public Health (Boston, MA, U.S.A.).
ABOUT STALLERGENES GREER INTERNATIONAL AG
Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of allergies through the research, development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit www.stallergenesgreer.com.
ABOUT FONDATION DE FRANCE
Created in 1969, Fondation de France is a private organisation recognised of public interest, whose mission is to support all forms of generosity in order to translate them into effective actions of general interest. With the 945 foundations it hosts, it supports more than 10,000 promising and innovative initiatives each year, in France and abroad. Independent and private, it operates thanks to the generosity of donors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005514/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TestMu AI Introduces the Source-to-Verdict Loop in Kane CLI, Carrying Every Requirement to a Ship Decision With Portable Proof23.7.2026 15:45:00 CEST | Press release
Kane CLI now takes a requirement all the way to a ship-or-hold verdict, designing the tests, running them in a real browser, and emitting an open .evidence proof pack that teammates, AI agents, and auditors can all verify, with no server or dashboard required TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, introduced a source-to-verdict loop in Kane CLI, its natural-language testing tool. Building on Kane CLI's evolution from a browser automation tool, the loop carries a product requirement to a ship decision, writing the tests, running them in the local browser, collecting the proof, measuring coverage from what actually happened, and returning a verdict. As AI agents write, run, and fix tests, a green checkmark is no longer enough: a step that checks nothing passes, a test written against a spec that changed weeks ago passes, and an agent that says “done” without the click ever landing passes. Empty green and earned green are the sa
Norway’s health system adopts Wolters Kluwer UpToDate Enterprise Edition23.7.2026 15:30:00 CEST | Press release
Enterprise Clinical Decision Support solution available to 30,000 clinicians in more than 50 Norwegian hospitals Wolters Kluwer Health announced that Norway’s health system has renewed its adoption of UpToDate Enterprise Edition, a market-leading Clinical Decision Support (CDS) solution, for its nationwide health system which includes over 50 public hospitals and 11,000 beds in over 20 trusts. This extends a 15 year partnership with Helsebiblioteket, now part of the Norwegian Institute of Public Health (NIPH). Helping clinicians on a national scale Kjell Tjensvoll, Team Leader for Helsebiblioteket said, ‘‘Providing frontline teams with easy access to the latest medical knowledge is vital in reducing unwarranted variation and improving patient care on a national scale. UpToDate Enterprise Edition enables this, and we are delighted to strengthen our relationship with Wolters Kluwer and provide continued support for clinicians across the country.’’ UpToDate Enterprise Edition was selected
Boyd Watterson Global Names John Creswell Global Chief Client Officer to Accelerate Global Growth and Client Engagement23.7.2026 15:00:00 CEST | Press release
Veteran investment management executive will lead global sales, client engagement and marketing as Boyd Watterson Global continues expanding its global alternatives platform across real estate, infrastructure, and debt strategies. Boyd Watterson Global today announced the appointment of John Creswell as Global Chief Client Officer, a newly created senior leadership role that reflects the firm's continued investment in growth and its evolution into a leading global alternatives investment platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722823117/en/ John Creswell has joined Boyd Watterson Global as Global Chief Client Officer, a newly created role overseeing global sales, client engagement and marketing across the U.S., Europe and APAC. In this role, Creswell will oversee global sales, client engagement and marketing efforts across the United States, Europe and APAC, helping investors access the firm's capabilitie
Trulioo Launches AI Agent to Resolve Beneficial Ownership Where Global Registries Fall Short23.7.2026 15:00:00 CEST | Press release
Breakthrough AI agent reconstructs ownership for long-tail businesses and hard-to-reach jurisdictions while significantly increasing UBO coverage Trulioo, a global risk intelligence platform, today announced the UBO Discovery Agent, the newest layer in Trulioo's UBO Discovery capability inside its business risk and Know Your Business (KYB) verification workflow. AI is reshaping fraud, making it easier for bad actors to hide, and harder for companies to catch them. This makes the already tough job of verifying who actually owns a business even more difficult. Determining a business's ultimate beneficial owner is an ongoing, acute challenge for companies: registry coverage is inconsistent across countries, and even where registries exist, they typically record shareholders and directors of record (rather than the people actually in control). That data isn't simply outdated, it reflects a structural lag: ownership changes and time passes before the filing is made and processed, so a looku
Humanoid Raises $152 Million at $1.35 Billion Post-Money Valuation, Becoming Europe's First Pure-Play Humanoid Robotics Unicorn23.7.2026 15:00:00 CEST | Press release
Humanoid announces its Series A investment round, reaching a $1.35 billion valuation just two years after founding.It is the largest ever Series A for a humanoid-first robotics company in Europe, positioning Humanoid as the leading humanoid-first robotics unicorn in the UK and continental Europe.The new capital will accelerate Humanoid's next-generation robot development, commercial deployments with global industrial leaders, and evolution of the proprietary AI platform on the path toward general-purpose humanoids.The investment marks a defining moment for Europe's tech ecosystem, showing that globally competitive Physical AI companies can be built and scaled in Europe. Humanoid, a UK-based AI and robotics company building industrial humanoid robots, announced a $152 million Series A financing at a $1.35 billion post-money valuation. This funding brings the total amount raised to date to $270 million. The round was led by Prime Movers Lab, a venture capital firm focused on investments
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom